Fifth Third Bancorp Purchases 56,151 Shares of IQVIA Holdings Inc. $IQV

Fifth Third Bancorp boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 248.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 78,755 shares of the medical research company’s stock after purchasing an additional 56,151 shares during the quarter. Fifth Third Bancorp’s holdings in IQVIA were worth $13,431,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. WealthShield Partners LLC bought a new stake in shares of IQVIA in the 1st quarter valued at $1,741,000. Sequoia Financial Advisors LLC lifted its holdings in IQVIA by 16.9% during the first quarter. Sequoia Financial Advisors LLC now owns 9,811 shares of the medical research company’s stock worth $1,673,000 after acquiring an additional 1,421 shares in the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in IQVIA by 335.8% during the first quarter. Kornitzer Capital Management Inc. KS now owns 46,200 shares of the medical research company’s stock worth $7,879,000 after acquiring an additional 35,600 shares in the last quarter. Carmel Capital Partners LLC grew its stake in IQVIA by 14.2% in the first quarter. Carmel Capital Partners LLC now owns 17,226 shares of the medical research company’s stock valued at $2,938,000 after acquiring an additional 2,137 shares during the period. Finally, Equitable Trust Co. raised its position in shares of IQVIA by 3.7% during the first quarter. Equitable Trust Co. now owns 14,828 shares of the medical research company’s stock worth $2,529,000 after purchasing an additional 527 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday. HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Robert W. Baird increased their price objective on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a report on Thursday, July 9th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Stock Up 0.2%

IQVIA stock opened at $208.00 on Wednesday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04. The company has a fifty day simple moving average of $183.23 and a 200 day simple moving average of $188.27. The company has a market cap of $34.72 billion, a P/E ratio of 25.78, a price-to-earnings-growth ratio of 1.78 and a beta of 1.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has authorized a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.